Navigation Links
Corgenix Expands Scientific Advisory Board
Date:6/17/2008

DENVER, June 17 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, announced today the appointment of Barry L. Molk, M.D., F.A.C.C., and Charles H. Miranda, M.D., F.A.C.P., F.A.A.P., to its scientific advisory board.

Drs. Molk and Miranda join Luis Lopez, M.D., Corgenix Chairman and Chief Medical Officer, expanding the number of scientific advisory board members to three.

"These two individuals bring a wealth of knowledge and expertise to our organization," said Douglass Simpson, Corgenix' President and Chief Executive Officer. "Their appointment strengthens the clinical and scientific guidance required for the successful development, manufacturing and marketing of our diagnostic testing products."

Dr. Molk has been affiliated with Aurora Denver Cardiology Associates since 1976 and has served as Chief of Cardiology at Sky Ridge Medical Center since 2003. He is board certified in internal medicine and cardiovascular diseases and is also a Fellow of the American College of Cardiology (F.A.C.C.).

After receiving his medical degree from the University of Colorado Health Sciences Center (UCHSC), Dr. Molk completed his residency training at Baylor Affiliated Hospitals and UCHSC, and is fellowship trained in cardiology from UCHSC. He maintains a teaching appointment as Associate Clinical Professor of Medicine, UCHSC.

Dr. Miranda is currently in private practice in internal medicine and pediatrics at South Denver Internal Medicine and Pediatrics, P.C. in Denver. Previously, he practiced internal medicine and pediatrics for 10 years at the world-renowned Texas Medical Center in Houston. Miranda is board certified by the American Board of Internal Medicine and the American Board of Pediatrics. He is a Fellow of the American Academy of Pediatrics (F.A.A.P.) and the American College of Physicians (F.A.C.P.).

Dr. Miranda received his medical degree from the University of California, San Francisco (UCSF). He completed specialty training in both internal medicine and pediatrics at Baylor College of Medicine in Houston, Texas. He is also a clinical instructor in the department of medicine at UCHSC.

Corgenix periodically draws on the expertise of advisors and consultants in fields related to its technology and markets. These members are available to Corgenix as needed on an individual basis to provide advice with respect to clinical medicine and other matters requiring scientific expertise. Non-employee members of the scientific advisory board are compensated for their participation.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
2. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
3. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
4. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
5. Corgenix Signs Technology Licensing Agreement With Japanese Government
6. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
7. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
8. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
9. ThreeWire Expands Presence in the Pharmaceutical Arena
10. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
11. DuPont Expands Animal Health Solutions Business in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... IPSWICH, Mass. , Feb. 17, 2017 /PRNewswire/ ... a small tumor had a mutation-conferring resistance to ... treatment. Recently, genomics research has focused on finding ... — or even from circulating tumor DNA in ... identify new oncology therapeutics. Unfortunately, however, ...
(Date:2/16/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing ... treatment for triple negative breast cancer (TNBC), announced today their ... program. The YEi Start in ... entrepreneurs grow their business in France ... selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
Breaking Biology Technology:
(Date:1/21/2017)... Research and Markets has announced the addition ... to their offering. ... The global voice recognition biometrics market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
Breaking Biology News(10 mins):